Cancer Management and Research (Sep 2019)
The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis
Abstract
Yan Wang*, Pengfei Li*, Jue Li, Yutian Lai, Kun Zhou, Xin Wang, Guowei Che Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Guowei CheDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Guoxuexiang No. 37, Chengdu, People’s Republic of ChinaTel +86 281 898 060 1890Fax +86 288 542 2494Email [email protected]: To examine the predictive role of Glasgow Prognostic Score (GPS) on long-term survival in esophageal cancer.Method: Comprehensive searches of electronic databases were performed to identify potential studies that evaluated the prognostic value of pretreatment GPS in esophageal cancer patients. We combined the hazard ratios (HRs) with 95% confidence intervals (CIs) to assess the association of GPS with overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS).Results: A total of 21 studies including 6115 patients were analyzed. Compared with patients with GPS 0, patients with elevated GPS had poorer OS (HR =2.12, 95% CI: 1.83–2.45, P<0.001) and CSS (HR =2.16, 95% CI: 1.56–2.98, P<0.001); but no significant relationship was observed between the elevated GPS and DFS (HR=2.14, 95% CI:1.00–4.61, P=0.051). Subgroup analysis outcomes were similar to overall analyses.Conclusion: Pretreatment GPS could serve as a valuable factor in predicting the prognosis of patients with esophageal cancer. More well-designed prospective studies are warranted to confirm our findings.Keywords: esophageal cancer, Glasgow Prognostic Score, survival, meta-analysis
